---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029851"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:10:23.406429+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio ADI-001 Phase 1 shows 71% ORR; pivots to Phase 2 in 1H24

## Summary
- ADI-001 achieved 71% ORR & 63% CR across doses in heavily pre-treated NHL (median 4 prior lines; 50% post-CAR T).
- At RP2D (1B cells), CR rate 63%, 6-month CR rate 25%; in post-CAR T patients CR rate 67% (6-month CR 33%).
- No GvHD; only 1 Grade 3+ CRS and 1 Grade 3+ ICANS among 24 safety-evaluable patients.
- FDA Type B meeting completed; plan to start potentially pivotal Phase 2 in post-CAR T LBCL in 1H 2024.
- ADI-001 persistence at RP2D (Cmax 483 cells/µL day 9) exceeded approved autologous CD19 CAR T.

## SEC filing metadata
- accession: 0000950170-23-029851
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017023029851/0000950170-23-029851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017023029851/acet-20230626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029851
- JSON: https://secwatch.observer/filing/0000950170-23-029851.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.